PH13894A - A gabergic composition and its use as potentiator of neuroleptic drugs in the treatment of schizophrenia - Google Patents
A gabergic composition and its use as potentiator of neuroleptic drugs in the treatment of schizophreniaInfo
- Publication number
- PH13894A PH13894A PH17222A PH17222A PH13894A PH 13894 A PH13894 A PH 13894A PH 17222 A PH17222 A PH 17222A PH 17222 A PH17222 A PH 17222A PH 13894 A PH13894 A PH 13894A
- Authority
- PH
- Philippines
- Prior art keywords
- gabergic
- potentiator
- schizophrenia
- treatment
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/475,856 US3947579A (en) | 1974-06-03 | 1974-06-03 | Method and composition for potentiating neuroleptic drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH13894A true PH13894A (en) | 1980-10-27 |
Family
ID=23889440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH17222A PH13894A (en) | 1974-06-03 | 1975-06-03 | A gabergic composition and its use as potentiator of neuroleptic drugs in the treatment of schizophrenia |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US3947579A (fr) |
| AU (1) | AU499034B2 (fr) |
| BE (1) | BE829830A (fr) |
| CA (1) | CA1048932A (fr) |
| DE (1) | DE2523998A1 (fr) |
| FR (1) | FR2272646B1 (fr) |
| GB (2) | GB1514311A (fr) |
| IE (1) | IE41374B1 (fr) |
| IL (1) | IL47324A (fr) |
| NL (1) | NL7506404A (fr) |
| PH (1) | PH13894A (fr) |
| ZA (1) | ZA753316B (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2453643A2 (fr) * | 1977-06-24 | 1980-11-07 | Synthelabo | Compositions pharmaceutiques actives sur le systeme nerveux central |
| US4160835A (en) * | 1976-11-19 | 1979-07-10 | Merck & Co., Inc. | Antihypertensive compositions containing an arylsubstituted alanine and a phenyl hydrazinopropionic acid |
| NL7706429A (nl) * | 1977-06-10 | 1978-12-12 | Univ Erasmus | Werkwijze voor de bereiding van een geneesmid- del met angst en angstequivalenten opheffende werking en gevormd geneesmiddel met een derge- lijke werking. |
| US4148896A (en) * | 1978-02-22 | 1979-04-10 | E. I. Du Pont De Nemours And Company | Antidepressant combination |
| US4346085A (en) * | 1980-02-29 | 1982-08-24 | Massachusetts Institute Of Technology | Process and composition for treating disorders by administering amphetamine and choline |
| NL8006135A (nl) * | 1980-11-10 | 1982-06-01 | Univ Erasmus | Geneesmiddel met angst en angstequivalenten opheffende werking en werkwijze voor de bereiding van een dergelijk geneesmiddel. |
| US4636494A (en) * | 1981-01-30 | 1987-01-13 | Massachusetts Institute Of Technology | Process and composition for treating disorders by administering amphetamine and choline |
| DK373383A (da) | 1982-08-20 | 1984-02-21 | Midit | Fremgangsmaade til fremstilling af omega-aminosyrederivater |
| US5296277A (en) * | 1992-06-26 | 1994-03-22 | Minnesota Mining And Manufacturing Company | Positionable and repositionable adhesive articles |
| US5637617A (en) * | 1994-04-01 | 1997-06-10 | The Regents Of The University Of California | Methods for use of GABAa receptor GABAergic compounds |
| US20050192220A1 (en) * | 2001-02-05 | 2005-09-01 | Gevys Pharmaceuticas Ltd. | Composition and method for potentiating drugs |
| US6833377B2 (en) | 2001-02-05 | 2004-12-21 | Gevys Pharmaceuticals Ltd. | Composition and method for potentiating drugs |
| US7544681B2 (en) | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| ES2379544T3 (es) | 2001-09-27 | 2012-04-27 | Ramot At Tel Aviv University Ltd. | Conjugado de perfenazina y GABA y usos del mismo |
| EP2272537A3 (fr) * | 2005-06-07 | 2014-10-22 | Ramot at Tel-Aviv University Ltd. | Sels de conjuguées de médicaments psychotropiques et procédés pour leur synthèse |
| CA2610838A1 (fr) * | 2005-06-07 | 2006-12-14 | Ramot At Tel Aviv University Ltd. | Nouveaux sels de medicaments psychotropes conjugues et leurs procedes de preparation |
| WO2008010223A2 (fr) | 2006-07-17 | 2008-01-24 | Ramot At Tel Aviv University Ltd. | Conjugués de gaba anti-douleur |
| US8207369B2 (en) | 2008-02-11 | 2012-06-26 | Ramot At Tel-Aviv University Ltd. | Conjugates for treating neurodegenerative diseases and disorders |
| EP2291181B9 (fr) | 2008-04-18 | 2013-09-11 | University College Dublin National University Of Ireland, Dublin | Utilisation de la captodiamine pour le traitement des symptômes de la dépression |
| EP2509603A1 (fr) | 2009-12-09 | 2012-10-17 | Biolinerx Ltd. | Procédés d'amélioration des fonctions cognitives |
| WO2012038963A1 (fr) | 2010-09-22 | 2012-03-29 | Ramot At Tel-Aviv University Ltd. | Sel d'addition d'acide d'un conjugué nortriptyline-gaba et son procédé de préparation |
| WO2016176609A1 (fr) | 2015-04-30 | 2016-11-03 | Ovid Therapeutics Inc | Procédés de traitement du syndrome de prader-willi |
| US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| WO2017205606A1 (fr) | 2016-05-26 | 2017-11-30 | Ovid Therapeutics Inc. | Procédés de traitement de syndromes du comportement à l'aide de pipradrol |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH449645A (de) * | 1963-07-09 | 1968-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer Aminosäuren |
| US3505451A (en) * | 1967-08-14 | 1970-04-07 | Geigy Chem Corp | Compositions and methods for alleviating schizophrenia employing one of haloperidol,trifluperidol or an acid addition salt thereof and one of desipramine,imipramine and an acid addition salt thereof |
-
1974
- 1974-06-03 US US05/475,856 patent/US3947579A/en not_active Expired - Lifetime
-
1975
- 1975-04-30 FR FR7513709A patent/FR2272646B1/fr not_active Expired
- 1975-05-16 GB GB20777/75A patent/GB1514311A/en not_active Expired
- 1975-05-16 GB GB1591/78A patent/GB1514312A/en not_active Expired
- 1975-05-20 IL IL47324A patent/IL47324A/xx unknown
- 1975-05-22 AU AU81438/75A patent/AU499034B2/en not_active Expired
- 1975-05-22 ZA ZA00753316A patent/ZA753316B/xx unknown
- 1975-05-28 CA CA75227970A patent/CA1048932A/fr not_active Expired
- 1975-05-30 DE DE19752523998 patent/DE2523998A1/de not_active Ceased
- 1975-05-30 NL NL7506404A patent/NL7506404A/xx not_active Application Discontinuation
- 1975-06-03 BE BE156998A patent/BE829830A/fr not_active IP Right Cessation
- 1975-06-03 IE IE1237/75A patent/IE41374B1/xx unknown
- 1975-06-03 PH PH17222A patent/PH13894A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IE41374B1 (en) | 1979-12-19 |
| FR2272646A1 (fr) | 1975-12-26 |
| DE2523998A1 (de) | 1975-12-11 |
| US3947579A (en) | 1976-03-30 |
| GB1514312A (en) | 1978-06-14 |
| FR2272646B1 (fr) | 1978-11-10 |
| NL7506404A (nl) | 1975-12-05 |
| BE829830A (fr) | 1975-10-01 |
| IL47324A (en) | 1979-03-12 |
| AU8143875A (en) | 1976-11-25 |
| IE41374L (en) | 1975-12-03 |
| CA1048932A (fr) | 1979-02-20 |
| ZA753316B (en) | 1976-04-28 |
| GB1514311A (en) | 1978-06-14 |
| IL47324A0 (en) | 1975-08-31 |
| AU499034B2 (en) | 1979-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH13894A (en) | A gabergic composition and its use as potentiator of neuroleptic drugs in the treatment of schizophrenia | |
| CY1125A (en) | 2-(heterocaclic asbstituted alkylsulphinyl)-benzinmidazoles and their pharmaceutical compositions | |
| NZ179495A (en) | 1-substituted-4-benzylpiperidines and pharmaceutical compositions | |
| NZ180529A (en) | Erythromyc-9-yl-amine derivatives and pharmaceutical compositions | |
| IL47625A0 (en) | Novel quinazoline derivatives and pharmaceutical compositions containing them | |
| JPS51115910A (en) | Gradually releaseetype medical composition and its preparation | |
| ZA763917B (en) | Pharmaceutical compositions and compounds | |
| JPS5262273A (en) | Ppoduction of benzisothiazolone and pharmaceutical composition | |
| JPS5262263A (en) | Esteranic steroid and pharmaceutical composition thereof | |
| JPS5242834A (en) | Diphenylamines* preparation thereof and its use | |
| GB1520584A (en) | 2 - alkoxy - 5 substituted benzamide derivatives and their use in pharmaceutical compositions | |
| ZA756869B (en) | Sterilising compositions and their use | |
| NZ181503A (en) | Substituted diphenyls-ulphides and pharmaceutical compositions | |
| NZ182591A (en) | 14-substituted-daunorubicins and pharmaceutical compositions | |
| JPS5362834A (en) | Pharmaceutical composition and use thereof | |
| NZ181864A (en) | Noroxymorphones and pharmaceutical compositions | |
| NZ182581A (en) | -amino-ketones and pharmaceutical compositions | |
| NZ182161A (en) | Alkoxy-pyridine-carobxamide derivatives and pharmaceutical compositions | |
| JPS53145905A (en) | Pharmaceutical composition and production thereof | |
| PH12590A (en) | 4a-aryl octahydro-1h-2-pyrindines and pharmaceutical composition thereof | |
| JPS5320433A (en) | Pharmaceutical composition and application | |
| NZ181727A (en) | Pyrroline-2-one derivatives and pharmaceutical compositions | |
| JPS527419A (en) | Heterocolloidal deblicin containing medical composition and its preparation | |
| NZ181401A (en) | 2-benzopyranone derivatives and pharmaceutical compositions | |
| NZ179598A (en) | Cephalosporins and pharmaceutical compositions |